trial · primary record
STX-721/PFL-721 (Escalated)
Non-Small Cell Lung Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 345 |
| Primary completion | 2029-12-01 |
| Primary endpoint | Part 1 Dose Escalation (MTD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatment |
| Registry ID | NCT06043817 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:06.479Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06043817
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.